ReviewCurrent oncology (Toronto, Ont.)2023
Surgical Management of Retroperitoneal Sarcoma.
Review in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Short-term perioperative safety and long-term follow-up after robotic-assisted resection of non-renal, non-adrenal retroperitoneal tumors: a 10-year retrospective cohort study.Translational andrology and urology · 2026Article
- Total laparoscopic R0 resection of a large retroperitoneal leiomyosarcoma HARBORING a rare TP53 mutation: a case report.Journal of surgical case reports · 2026Article
- Retroperitoneal ectopic spleen identified during emergency laparotomy.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2026Article
- Article
- A Comprehensive Review of Margin Identification Methods in Soft Tissue Sarcoma.Current oncology (Toronto, Ont.) · 2025Review
- Global trends in retroperitoneal sarcomas surgery: a bibliometric analysis from 2005 to 2024.Discover oncology · 2025Article
- Pathologic Complete Response to Neoadjuvant Radiation Therapy in a Primary Pancreaticoduodenal High-Grade Sarcoma.Cureus · 2025Article
- Surgical Management of Retroperitoneal Liposarcoma: Opportunities for Multimodality Treatment, Including Systemic Therapy.Cancer medicine · 2025Review
- Complete Resection of Giant and Well-Differentiated Retroperitoneal Liposarcoma: A Case Report.Cureus · 2025Article
- Imaging classification and surgical strategy of retroperitoneal vascular leiomyosarcoma: experience from a single medical center.BMC cancer · 2025Article
- Recurrent giant retroperitoneal dedifferentiated liposarcoma requiring challenging multiorgan resection: a case report.Journal of medical case reports · 2025Article
- Article
- Multiple surgical interventions improve survival in locally recurrent retroperitoneal sarcoma: a retrospective cohort analysis.Frontiers in oncology · 2025Article
- Retroperitoneal leiomyosarcoma mimicking an ovarian tumor diagnosed using a negative ovarian pedicle sign.Radiology case reports · 2024Article
- Resection of previously inoperable retroperitoneal liposarcoma.BMJ case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surgery is the cornerstone of treatment for retroperitoneal sarcoma (RPS). Surgery should be performed by a surgical oncologist with sub-specialization in this disease and in the context of a multidisciplinary team of sarcoma specialists. For primary RPS, the goal of surgery is to achieve the complete en bloc resection of the tumor along with involved organs and structures to maximize the clearance of the disease. The extent of resection also needs to consider the risk of complications. Unfortunately, the overarching challenge in primary RPS treatment is that even with optimal surgery, tumor recurrence occurs frequently. The pattern of recurrence after surgery (e.g., local versus distant) is strongly associated with the specific histologic type of RPS. Radiation and systemic therapy may improve outcomes in RPS and there is emerging data studying the benefit of non-surgical treatments in primary disease. Topics in need of further investigation include criteria for unresectability and management of locally recurrent disease. Moving forward, global collaboration among RPS specialists will be key for continuing to advance our understanding of this disease and find more effective treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.